CMS Logo "Residents of skilled nursing facilities (SNFs) are ideal for these novel therapies and long-term care (LTC) pharmacies provide intravenous medications (IV) routinely in SNF environments."

Two investigational SARS-CoV-2 neutralizing antibody treatments, bamlanivimab and casirivimab plus imdevimab are now available through Emergency Use Authorization (EUA) from the FDA for use in eligible outpatients with mild to moderate disease who are at high risk for disease progression and/or hospitalization. Both neutralizing antibodies might reduce the rate of hospitalizations and emergency room visits in high risk patients defined as age >65 years and underlying illnesses listed here.


ASCP published a Readiness Document developed in a collaboration between ASCP and AMDA - The Society for Post-Acute and Long Term Care Medicine.


For more information, please refer to ASCP's website